Mexico - Delayed Quote MXN

Roche Holding AG (ROGN.MX)

6,418.00

0.00

(0.00%)

At close: January 30 at 11:14:58 AM CST

Roche targets continued growth after strong 2024 sales

Roche achieved a sales growth of 7% (3% in CHF) in 2024, citing strong demand for pharmaceutical products.

Pharmaceutical Technology 14 hours ago

ROG.SW
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be eligible for a targeted treatment, which could significantly improve their outcomes. The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast

GlobeNewswire 17 hours ago

RHHBF

RHHBY

RHHVF
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

Zacks 18 hours ago

SNY

NVO

ROG.SW
Roche Holding AG (RHHVF) Expands AI in Digital Pathology and Drug Development, Reports 9% Sales Growth in Q3 2024

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHVF) stands against Morgan Stanley’s other European AI stocks. In August last year, investment bank Morgan Stanley released an investor note highlighting that even though the chaos […]

Insider Monkey yesterday

ROG.SW

MS-PQ
Roche Holding AG (RHHBF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...

Roche Holding AG (RHHBF) reports robust financial performance with a 7% sales growth and a 14% increase in core operating profit, while advancing its promising pharmaceutical pipeline.

GuruFocus.com yesterday

ROG.SW
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well

RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.

Zacks yesterday

ROG.SW
FDA grants 510(k) clearance to Roche’s Tina-quant molarity assay

Clinicians and laboratory professionals can rely on molar unit measurements to know the Lp(a) particle numbers.

Medical Device Network yesterday

ROG.SW
Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the CEO said it remained committed to keeping its R&D spending broadly flat in 2025.

The Wall Street Journal 2 days ago

RHHBF

RHHBY

RHHVF
Roche sees high single-digit core profit growth in 2025

FRANKFURT (Reuters) -Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year, helped by lower costs and growth from drugs such as eye treatment Vabysmo and cancer drug Phesgo. The goal, which is adjusted for currency swings, would mark continued earnings momentum as the Swiss drugs and diagnostics company said in its earnings statement that adjusted 2024 EPS rose 7%, also before foreign exchange effects. Analysts at Swiss bank Vontobel said the 2025 guidance was conservative, which was an expected stance taken by Roche.

Reuters 2 days ago

ROG.SW
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth

Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%. COVID-19 will not adversely impact our results from 2025 onwards.The fourth quarter was the third consecutive quarter of 9% sales growth, highlighting the very positive momentum.Pharmaceuticals Division sales rose by 8% (excluding COVID-19 medicine: 9%) on growing demand for newer medicines; top gro

GlobeNewswire 2 days ago

RHHBF

RHHBY

RHHVF
Roche appoints chief digital technology officer

Wafaa Mamilli will join the healthcare giant Feb. 10, reporting to CEO Thomas Schinecker.

CIO Dive 2 days ago

ROG.SW
Change to the Roche Enlarged Corporate Executive Committee

Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker, and will become a member of the enlarged Corporate Executive Committee starting 10 February 2025. She will be based at Genentech in South San Francisco. In this new role, she will take over the worldwide responsibility for the Informatics function for the Roche Group from Alan Hippe, who

GlobeNewswire 3 days ago

RHHBF

RHHBY

RHHVF
Roche reports positive topline outcomes from DMD treatment trial

Subjects from the first part of the trial maintained significant improvements in NSAA scores.

Clinical Trials Arena 3 days ago

ROG.SW
Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

Updated overall survival (OS) results - a key secondary endpoint - reinforce the significant benefit of the ItovebiTM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positive, HER2-negative breast cancer in the first-line setting Primary analysis showed the Itovebi-based regimen reached statistical significance, more than doubling progression-free survival in this patient population1Full OS results from the phase III INAVO120 study will be presented at an upcoming medica

GlobeNewswire 4 days ago

RHHBF

RHHBY

RHHVF
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer

SOUTH SAN FRANCISCO, Calif., January 28, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the overall survival (OS) analysis of the Phase III INAVO120 study investigating ItovebiTM (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine-resistant, locally advanced or metastatic b

Business Wire 4 days ago

RHHBF

RHHBY

RHHVF
Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

Across three key functional outcomes, North Star Ambulatory Assessment (NSAA), Time to Rise (TTR) and 10-meter walk/run (10MWR), results were statistically significant and clinically meaningful two years after treatment with Elevidys, compared to a pre-specified propensity-weighted untreated external control groupFunctional differences between individuals treated with Elevidys and those in the external control group increased between one year and two years after treatmentNo new safety signals ob

GlobeNewswire 5 days ago

RHHBF

RHHBY

RHHVF
Stocks to watch this week: ASML, Intel, LVMH, Shell and Glencore

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 7 days ago

AON

WHTPF

LMT
Roche’s STI assay panels gain FDA 510(k) clearance and CLIA waiver

Leveraging gold-standard PCR technology, the cobas liat system claims to deliver outcomes in under 20 minutes.

Medical Device Network 9 days ago

ROG.SW
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to accurate, easy-to-use diagnostics for all patients in decentralized settings like urgent care centers, retail clinics, and community health venues.The tests use highly sensitive, gold-standard PCR technology, providing results in 20 minutes to allow healthcare providers to confidently diagnose and d

GlobeNewswire 10 days ago

RHHBF

RHHBY

RHHVF
Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.

BioPharma Dive 15 days ago

ROG.SW

Performance Overview

Return	ROGN.MX	MSCI WORLD
YTD	+16.20%	+3.16%
1-Year	+30.17%	+18.53%
3-Year	-18.49%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Roche Holding AG (ROGN.MX)

Roche targets continued growth after strong 2024 sales

Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More

Roche Holding AG (RHHVF) Expands AI in Digital Pathology and Drug Development, Reports 9% Sales Growth in Q3 2024

Roche Holding AG (RHHBF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...

Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well

FDA grants 510(k) clearance to Roche’s Tina-quant molarity assay

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

Roche sees high single-digit core profit growth in 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth

Roche appoints chief digital technology officer

Change to the Roche Enlarged Corporate Executive Committee

Roche reports positive topline outcomes from DMD treatment trial

Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer

Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

Stocks to watch this week: ASML, Intel, LVMH, Shell and Glencore

Roche’s STI assay panels gain FDA 510(k) clearance and CLIA waiver

Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world

Performance Overview